Loading…
Vistagen Therapeutics, Inc. is projected to rise to $0.2775 by 2027, a +13% move from its current price of $0.245. VTGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.234 | $0.2451 | $0.2566 | +0.03% |
| Aug 6 | $0.2297 | $0.2452 | $0.2617 | +0.06% |
| Aug 7 | $0.2264 | $0.2452 | $0.2656 | +0.09% |
| Aug 8 | $0.2237 | $0.2453 | $0.269 | +0.12% |
| Aug 9 | $0.2213 | $0.2454 | $0.272 | +0.16% |
| Aug 10 | $0.2192 | $0.2455 | $0.2748 | +0.19% |
| Aug 11 | $0.2173 | $0.2455 | $0.2774 | +0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2173 | $0.2455 | $0.2774 | +0.22% |
| Week 2 | $0.2071 | $0.2461 | $0.2924 | +0.44% |
| Week 3 | $0.1996 | $0.2466 | $0.3046 | +0.66% |
| Week 4 | $0.1936 | $0.2471 | $0.3155 | +0.88% |
| Week 5 | $0.1885 | $0.2477 | $0.3254 | +1.10% |
| Week 6 | $0.1841 | $0.2482 | $0.3347 | +1.32% |
| Week 7 | $0.1801 | $0.2488 | $0.3436 | +1.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders. Its product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women’s health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
VTGN is a clinically focused biopharma name trading in a micro-cap space with a current price of $0.2292 and a market cap of $9.4M. It ranks 4956 in the market cap universe. The near-term price outlook is framed by a year-by-year forecast that starts neutral in 2026 and turns bullish in subsequent years, with meaningful upside potential reflected in later years.
The forecast shows a path of rising averages and sizable max values, indicating potential upside beyond the current price level. These are estimates and not guarantees.
A major floor 6.1% below — a decisive break under it would weaken the trend.
The nearest floor, 6.1% below — buyers have tended to step in here.
The nearest ceiling, 210.2% above — a clean break opens room to run.
A major ceiling 283.7% above — clearing it would confirm fresh momentum.
Key VTGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.236 | Buy | $0.2374 | Buy |
| MA 10 | $0.234 | Buy | $0.2408 | Buy |
| MA 20 | $0.2395 | Buy | $0.2777 | Sell |
| MA 50 | $0.4454 | Sell | $0.3979 | Sell |
| MA 100 | $0.5243 | Sell | $0.6181 | Sell |
| MA 200 | $1.38 | Sell | $1.13 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.94 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 4.39 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.00 | Sell |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -2.80 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 72.47 | Sell |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 0.24 | Buy |
| ADX (14) | 32.48 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bearish, with RSI(14) at 30. The stock has traded within a thirty-day range of $0.1539 to $0.3413, showing a bit of volatility around the current level. Support is listed at $0.23 and resistance at $0.76, suggesting a tight near-term band around the current price.
The SMA50 is $0.5238 and the SMA200 is $1.56, underscoring the recent pressure on price to break above longer-term moving averages. Annualized volatility is very high at 100%, reflecting substantial risk in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.23 | $0.245 | $0.3532 | 0% | Neutral | |
| $0.2076 | $0.2775 | $0.3993 | +13% | Neutral | |
| $0.2987 | $0.4205 | $0.6412 | +72% | Bullish | |
| $0.3336 | $0.4905 | $0.7818 | +100% | Bullish | |
| $0.3127 | $0.4782 | $0.7907 | +95% | Bullish | |
| $0.3107 | $0.4926 | $0.8406 | +101% | Bullish | |
| $0.3012 | $0.4941 | $0.8672 | +102% | Bullish | |
| $0.3121 | $0.5289 | $0.9519 | +116% | Bullish | |
| $0.3552 | $0.6212 | $1.14 | +154% | Bullish | |
| $0.4347 | $0.7838 | $1.47 | +220% | Bullish | |
| $0.4282 | $0.8927 | $1.83 | +264% | Bullish | |
| $0.8967 | $1.99 | $4.58 | +713% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.23 | $0.245 | $0.3219 | +0.00% |
| September 2026 | $0.2211 | $0.2667 | $0.3343 | +8.85% |
| October 2026 | $0.2065 | $0.2521 | $0.3216 | -5.48% |
| November 2026 | $0.2074 | $0.2556 | $0.3307 | +1.38% |
| December 2026 | $0.2168 | $0.2695 | $0.3532 | +5.47% |
Click any year to see its month-by-month VTGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VTGN to range from $0.23 to $0.3532 through 2026. The $0.245 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The VTGN price prediction for 2027 points to an average of $0.2775 (low $0.2076, high $0.3993) — a potential gain of +13% on today's $0.245. A consolidation phase looks the most probable path here.
In 2028, VTGN is projected to trade between $0.2987 and $0.6412, averaging $0.4205 — a potential gain of +72% from today's $0.245. That is up +52% on the projected 2027 average. Momentum favours further upside here.
Vistagen Therapeutics, Inc.'s 2029 outlook centres on $0.4905, within a $0.3336 to $0.7818 range. That is up +17% on the projected 2028 average. That marks a +100% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, VTGN could reach as high as $0.7907, with a base case around $0.4782 and support toward $0.3127 — roughly +95% from $0.245. Momentum favours further upside here.
Expect VTGN to range from $0.3107 to $0.8406 through 2031. The $0.4926 average target implies a +101% move from current prices. That is up +3% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The VTGN price prediction for 2032 points to an average of $0.4941 (low $0.3012, high $0.8672) — a potential gain of +102% on today's $0.245. Momentum favours further upside here.
In 2033, VTGN is projected to trade between $0.3121 and $0.9519, averaging $0.5289 — a potential gain of +116% from today's $0.245. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Vistagen Therapeutics, Inc.'s 2034 outlook centres on $0.6212, within a $0.3552 to $1.14 range. That is up +17% on the projected 2033 average. That marks a +154% change versus current levels. Momentum favours further upside here.
By 2035, VTGN could reach as high as $1.47, with a base case around $0.7838 and support toward $0.4347 — roughly +220% from $0.245. Buyers look set to stay in control over this stretch.
Expect VTGN to range from $0.4282 to $1.83 through 2040. The $0.8927 average target implies a +264% move from current prices. That is up +14% on the projected 2035 average. Momentum favours further upside here.
The VTGN price prediction for 2050 points to an average of $1.99 (low $0.8967, high $4.58) — a potential gain of +713% on today's $0.245. Buyers look set to stay in control over this stretch.
Investing $1,000 in VTGN today (≈ 4,081.632653 VTGN) could be worth
$8,133.5
+$7,133.5 (+713%) by 2050 · US Dollar
Based on the average projected VTGN price of $1.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTGNwould be worth at today's price.
$1,000 invested in VTGN on Jul 31, 2025 (≈ 348.43207 VTGN) would be worth
$85.37
-$914.63 (-91.5%) today · 0.09× · US Dollar
Based on a VTGN entry price of $2.87 vs. today's $0.245.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.23 | $1,065.22 | +6.5% |
| 1 month ago | $0.24 | $1,020.83 | +2.1% |
| 3 months ago | $0.63 | $388.89 | -61.1% |
| 6 months ago | $0.58 | $422.41 | -57.8% |
| 1 year ago | $2.87 | $85.37 | -91.5% |
| All time (5.0y) ago | $83.7 | $2.93 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTGN forecast.
Our base-case forecast reaches $0.49 around 2029.
Implied market cap at $0.49: $20.11M
The multi-year forecast points to a bullish trajectory over the long run. In 2026 the min and avg prices are $0.2292, with a max of $0.3383 and ROI of 0, sentiment Neutral. In 2028 the avg price rises to $0.4248 with ROI 85.3, continuing bullish sentiment into 2029 with an avg of $0.4742 and ROI 106.9.
The 2030 forecast shows an avg of $0.4355 with ROI 90 and a bullish stance, followed by continued gains into 2031 (avg $0.4827, ROI 110.6) and 2032 (avg $0.4452, ROI 94.2). The path remains bullish through 2033 (avg $0.45, ROI 96.3) and strengthens into 2034 (avg $0.5879, ROI 156.5) and 2035 (avg $0.729, ROI 218.1). By 2040 the average price is forecast at $0.8215 with ROI 258.4, and by 2050 it is $1.75 on average with ROI 662.4, both noted as bullish.
These figures imply substantial upside over time, but the forecast also carries uncertainty and volatility inherent in such long-horizon estimates.
Tap a question to reveal the answer.
For 2030 the forecast shows min $0.2695, avg $0.4355, max $0.7554, ROI 90, sentiment BULLISH.
The forecast includes multiple bullish years (e.g., 2028 avg $0.4248, ROI 85.3; 2029 avg $0.4742, ROI 106.9; 2030 avg $0.4355, ROI 90; 2040 avg $0.8215, ROI 258.4; 2050 avg $1.75, ROI 662.4) alongside a neutral starting year (2026 ROI 0, sentiment Neutral). These are estimates, not guarantees.
Yes. The max values show it reaching above $1 in several years: 2034 max $1.15, 2035 max $1.46, 2040 max $1.80, and 2050 max $4.02.
The near-term picture is Bearish with RSI14 at 30. The 30-day range is $0.1539 to $0.3413, with support at $0.23 and resistance at $0.76. The SMA50 is $0.5238 and the SMA200 is $1.56, and volatility is high at 100%.
Vistagen Therapeutics, Inc. Community Discussion
0Share your Vistagen Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.